Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib Plus Pembrolizumab Versus Pembrolizumab And Pemetrexed And Carboplatin or Cisplatin in Patients with Previously Untreated, KRAS G12C-Mutated, Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
National University Hospital
Trial Status: Ongoing, Recruiting
Principal Investigator(s):
Dr Gillianne Lai Geet Yi
Dr Huang Yiqing
Published by HT Digital Content Servi...